GlassScriptPhysician profile
Laura K Omalley
NPI 1366402216
$11,242.20
in general payments reported to CMS, 2019-2025
61 companies · $1,228 in 2025
The $1,228 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,561 · 2020: $977 · 2021: $1,283 · 2022: $2,066 · 2023: $2,185 · 2024: $1,942 · 2025: $1,228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,354.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,403.83 | 2019-2025 | |
| Amgen INC. | $1,602.18 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $1,292.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $605.98 | 2022-2025 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $537.53 | 2019-2025 | |
| Lilly USA, LLC | $507.75 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Abbott Laboratories | $438.97 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $394.88 | 2019-2024 | Xifaxan |
| Allergan, INC. | $286.22 | 2019-2020 | |
| Amarin Pharma, INC. | $201.29 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $193.72 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $193.10 | 2019-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.06 | 2019-2022 | |
| Eisai INC. | $151.79 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $151.66 | 2019-2021 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Omalley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.